scholarly journals Cost-effectiveness of elbasvir/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States

2016 ◽  
Vol 24 (4) ◽  
pp. 268-279 ◽  
Author(s):  
E. Elbasha ◽  
W. Greaves ◽  
D. Roth ◽  
C. Nwankwo
Keyword(s):  
United States ◽  
Chronic Kidney Disease ◽  
Hepatitis C Virus ◽  
Cost Effectiveness ◽  
Hepatitis C ◽  
Kidney Disease ◽  
The United States ◽  
Genotype 1 ◽  
Virus Genotype ◽  
Treatment Naïve

scholarly journals FP267C-SURFER: GRAZOPREVIR PLUS ELBASVIR IN TREATMENT-NAIVE AND TREATMENT-EXPERIENCED PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION AND CHRONIC KIDNEY DISEASE

2015 ◽  
Vol 30 (suppl_3) ◽  
pp. iii156-iii156 ◽  
Author(s):  
Annette Bruchfeld ◽  
David Roth ◽  
David Nelson ◽  
AnneMarie Liapakis ◽  
Marcelo Silva ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Kidney Disease ◽  
Genotype 1 ◽  
Virus Genotype ◽  
Treatment Naïve

scholarly journals Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population

2016 ◽  
Vol 176 (1) ◽  
pp. 65 ◽  
Author(s):  
Harinder S. Chahal ◽  
Elliot A. Marseille ◽  
Jeffrey A. Tice ◽  
Steve D. Pearson ◽  
Daniel A. Ollendorf ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Cost Effectiveness ◽  
Hepatitis C ◽  
Liver Fibrosis ◽  
Early Treatment ◽  
Genotype 1 ◽  
Virus Genotype ◽  
Treatment Naïve
Sign in / Sign up

Export Citation Format

Share Document